Head-to-head · WeighScore
Direct Meds vs RX Bella
By GLP-1 ScorecardUpdated
Score comparison
Direct Meds has the higher recorded score — 77.6/100 to 67.8/100.
Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Direct Meds prices compounded injections and sublingual bottles separately; compare the renewal charge and early cancellation cutoff before choosing a plan.
Before you choose
Before comparing the headline prices, the Direct Meds review and the RX Bella review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Direct Meds vs SkinnyRx and ElleS vs RX Bella compare each of them with another graded program, and the list of alternatives to Direct Meds ranks the programs closest to Direct Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Direct Meds | RX Bella |
|---|---|---|
| WeighScore | 77.6/100 | 67.8/100 |
| Grade | C+ | C |
| Site position | #33 | #171 |
| Semaglutide | $249/30 days sublingual · $297/mo injectable | From $249/mo (a floor, not a rate) |
| Tirzepatide | $299/30 days sublingual · $399/mo injectable | From $299/mo (a floor, not a rate) |
| Coverage | Not publicly listed | Nationwide telehealth, claimed |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #33 · C+
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Strengths
- Injection and sublingual preparations have separately published prices
- Pricing page advertises medication, evaluation, supplies, shipping and nurse access
- Both semaglutide and tirzepatide are listed
- Checked semaglutide campaign states $147 initially, then $297 monthly
What to consider
- Compounded preparations are not FDA-approved products or assumed equivalent across routes
- No-subscription FAQ wording conflicts with the agreement's 30-day recurring charges
- Renewal cancellation requires 48-hour notice; initial-order cancellation has a separate conditional 24-hour window
- Assigned prescribing practice, dispensing pharmacy and selected longer-plan total need confirmation
- Checked campaign excludes Mississippi and Louisiana; confirm state eligibility
Strengths
- All four programs — microdose, oral, semaglutide injection, tirzepatide injection — carry a figure on the homepage before any intake
- Nothing in the catalog is struck through: no invented "was" price and no expiring offer
- "$0 if you're not approved" is stated plainly and repeatedly
- The online provider visit, prescription, delivery and ongoing check-ins are stated as included
What to consider
- The hero's "from $199/mo" is the microdose; the tirzepatide program is $299
- Every figure is a floor, no dose ladder is published, and the eight-screen intake reaches an email gate without showing a price
- Its own treatment pages carry no dollar figure and read "AVAILABLE BY CONSULTATION"
- No lab or monitoring requirement is published
- The compounding pharmacies are never named and the footer names no company
Featured provider
Direct Meds
Direct Meds scores 77.6/100 (C+). Direct Meds prices compounded injections and sublingual bottles separately; compare the renewal charge and early cancellation cutoff before choosing a plan.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.